CN111700116A - Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof - Google Patents
Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof Download PDFInfo
- Publication number
- CN111700116A CN111700116A CN202010465735.7A CN202010465735A CN111700116A CN 111700116 A CN111700116 A CN 111700116A CN 202010465735 A CN202010465735 A CN 202010465735A CN 111700116 A CN111700116 A CN 111700116A
- Authority
- CN
- China
- Prior art keywords
- powder
- solid beverage
- intestinal
- intestinal diseases
- stachyose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 26
- 239000007787 solid Substances 0.000 title claims abstract description 26
- 208000028774 intestinal disease Diseases 0.000 title claims abstract description 21
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 54
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 17
- 239000006041 probiotic Substances 0.000 claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 claims abstract description 16
- 239000002131 composite material Substances 0.000 claims abstract description 15
- 235000020248 camel milk Nutrition 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 8
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 7
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 7
- 241000193403 Clostridium Species 0.000 claims abstract description 6
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims abstract description 6
- 235000003570 Phyllostachys pubescens Nutrition 0.000 claims abstract description 6
- 244000134552 Plantago ovata Species 0.000 claims abstract description 6
- 235000003421 Plantago ovata Nutrition 0.000 claims abstract description 6
- 235000020251 goat milk Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- -1 aldehyde ketone Chemical class 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 244000302661 Phyllostachys pubescens Species 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 4
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 4
- 240000009088 Fragaria x ananassa Species 0.000 claims description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- 235000012255 calcium oxide Nutrition 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000004262 preparative liquid chromatography Methods 0.000 claims 1
- 238000011403 purification operation Methods 0.000 claims 1
- 235000020254 sheep milk Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 15
- 230000000968 intestinal effect Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 230000000770 proinflammatory effect Effects 0.000 abstract description 5
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 210000001072 colon Anatomy 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000008855 peristalsis Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 210000002460 smooth muscle Anatomy 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 abstract description 2
- 241001520913 Phyllostachys edulis Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000007413 intestinal health Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001466453 Laminaria Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/157—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a solid beverage for adjuvant therapy of intestinal diseases and a preparation method and application thereof, wherein the solid beverage comprises the following raw materials: camel milk powder, goat milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys pubescens leaf powder, thallus laminariae powder and composite probiotics; wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis. The camel milk can inhibit the damage of unsaturated aldehyde ketone in vivo to the smooth muscle of the intestinal tract, promote the functional repair of intestinal peristalsis, and simultaneously, can also enable beneficial bacteria in the intestinal tract to rapidly propagate to form a strong beneficial bacteria group so as to inhibit harmful bacteria in the intestinal tract and build a healthy intestinal microbial environment; camel milk, stachyose and composite probiotics can cooperate with each other to reduce the secretion of proinflammatory cytokine IFN-gamma and improve the damage of colon tissues and the immune protection effect.
Description
Technical Field
The invention relates to the technical field of functional foods, in particular to a solid beverage for adjuvant therapy of intestinal diseases and a preparation method and application thereof.
Background
The intestinal tract is an important digestive organ of a human body and also a maximum immune and toxin expelling organ of the human body, and has a great influence on the health of the human body. More than 80% of health problems in humans are caused by the intestinal tract, such as: constipation, diarrhea, halitosis, pachylosis, mottle, belly, hypertension, hyperlipidemia, gastroenteritis, etc., because when the intestinal tract fails to operate normally, the toxins in the body are discharged out of the body through other ducts (kidney, skin, respiration). Therefore, the improvement of the intestinal health has important significance on the human health.
The enhancement of the intestinal immune system is an important way for assisting in treating intestinal diseases and improving intestinal health, and the intestinal immune system consists of intestinal related lymphoid tissues, intestinal mucosal immune cells, immune media and the like and is also an important component of the body immune system. The intestinal mucosal immune cells typically exhibit immune tolerance to the normal microbiota and food antigens in the gut, while evoking an immune response to pathogenic microorganisms, producing an immune response. Cytokines are small molecular proteins with a wide range of biological activities synthesized and secreted by immune cells (such as monocytes, macrophages, T cells, B cells, NK cells, etc.) and certain non-immune cells (endothelial cells, epidermal cells, fibroblasts, etc.), and have important roles in immune responses of the body, and have various biological functions, such as regulation of cell growth, differentiation maturation, functional maintenance, regulation of immune responses, participation in inflammatory reactions, wound healing, tumor growth, and the like. Relevant researches show that the initiation of the intestinal inflammation and the chronization of the intestinal inflammation are largely related to the imbalance of proinflammatory cytokines and anti-inflammatory cytokines, and once the balance of the proinflammatory cytokines and the anti-inflammatory cytokines is broken, immune cells can also cause immune response to normal flora and food antigens, so that inflammatory reaction is generated. Therefore, regulation of gut cytokines to maintain a balance between pro-inflammatory and anti-inflammatory cytokines is of great importance to enhance the gut immune system.
The functional food is food with specific nutrition and health care functions, and more research results show that the functional food exerts the functional characteristics by influencing the human health through the cytokine network of the organism. Therefore, if a functional food capable of regulating and controlling body cytokines can be developed, the functional food has important significance for the adjuvant therapy of intestinal diseases.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art. Therefore, the invention provides the solid beverage which can be used for assisting in treating intestinal diseases by regulating and controlling the level of the intestinal cell factors.
The invention also provides a preparation method of the solid beverage.
The invention also provides application of the solid beverage.
According to the first aspect of the invention, the solid beverage is prepared from the raw materials comprising: camel milk powder, goat milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys pubescens leaf powder, thallus laminariae powder and composite probiotics;
wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis.
The solid beverage according to the embodiment of the invention has at least the following beneficial effects: the camel milk can inhibit the damage of unsaturated aldehyde ketone in vivo to the smooth muscle of the intestinal tract, promote the functional repair of intestinal peristalsis, and simultaneously, can also enable beneficial bacteria in the intestinal tract to rapidly propagate to form a strong beneficial bacteria group so as to inhibit harmful bacteria in the intestinal tract and build a healthy intestinal microbial environment; stachyose has obvious proliferation effect on beneficial bacteria such as bifidobacterium, lactobacillus and the like in intestinal tract, can quickly improve the environment in the digestive tract of a human body, regulate the balance of microbial flora, adsorb toxic substances and pathogenic bacteria in the gastrointestinal tract, improve the disease resistance of the body and enhance the immunity; in the composite probiotics, the bifidobacterium bifidum and the lactobacillus can inhibit the proliferation of Th2 type cells and promote the proliferation of Th1 type cells, the Th1 type cells can inhibit the proliferation of Th2 type cells, and the Th2 cells can inhibit the secretion of IFN-gamma by the Th1 type cells; therefore, camel milk, stachyose, composite probiotics and the like can cooperate with each other to reduce the secretion of proinflammatory cytokine IFN-gamma, and improve the damage of colon tissues and the immune protection effect. Meanwhile, the short-chain fatty acid, Plantago ovata husk and dietary fiber substances contained in oat flour which are rich in the goat milk powder are fermented and decomposed by lactobacillus plantarum, streptococcus thermophilus and the like to generate the short-chain fatty acid and polysaccharide components contained in lophatherum gracile and kelp, so that the intestinal epithelial barrier function and the immune tolerance can be synergistically enhanced, the intestinal homeostasis is promoted, an inflammasome is activated, and then interleukins (such as IL-18, IL-12, IL13 and the like) are generated, the secretion of IgA is increased through B cells, the expression of T cell activating molecules in antigen presenting cells is reduced, and the number and the function of regulatory T cells (including anti-inflammatory cytokines such as transforming growth factor-beta, IL-10 and the like) are increased.
According to some embodiments of the invention, the preparation raw materials further comprise a flavoring agent, the flavoring agent comprising lemon powder, strawberry powder, orange powder, and green plum powder; preferably, the mass ratio of the lemon powder, the strawberry powder, the fragrant orange powder and the green plum powder is (2-3): 1-5): 2-4): 1-3. The flavoring agent is compounded by a plurality of fruit powders, so that the taste is adjusted, and meanwhile, the vitamin can be supplemented, and the immunity of the organism is further improved and enhanced.
According to some embodiments of the present invention, the weight ratio of camel milk powder, goat milk powder, stachyose, oat powder, psyllium husk powder, phyllostachys edulis leaf powder, laminaria powder and composite probiotics is (40-50): 30-35): 2-5): 2-8): 1-5): 1-8): 5-10.
According to some embodiments of the invention, the mass ratio of Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium bifidum, Clostridium and Lactobacillus lactis is (2-4): 2-5: (2-4): 1-4: 3-5.
According to some embodiments of the invention, the number of viable bacteria in the composite probiotic is not less than 109CFU/g。
According to some embodiments of the invention, the stachyose is prepared by the following steps:
adding cordyceps sinensis and ginseng into water with the temperature of 50-80 ℃, ultrasonically leaching for 1-2 hours, and squeezing to obtain a crude extract;
adding yeast into the crude extract for fermentation to obtain fermentation liquor;
adding quicklime into the fermentation liquor until the fermentation liquor is saturated, heating to 50-55 ℃, and introducing carbon dioxide to generate calcium carbonate precipitate;
filtering, collecting filtrate, purifying, concentrating, and drying to obtain stachyose.
According to some embodiments of the invention, the ultrasonic power of the ultrasonic leaching is 200-300W.
According to some embodiments of the invention, the conditions during the fermentation are: the pH value of the reaction system is between 4 and 5, and the fermentation is carried out for 20 to 30 hours at the temperature of between 35 and 38 ℃ in a ventilating way.
According to some embodiments of the invention, the filtration is ultrafiltration.
According to some embodiments of the invention, the purifying is performed by: and (3) performing high-pressure liquid chromatography on the filtrate by using an aminopropyl bonded silica gel column, using acetonitrile-water as an eluent, performing constant-current elution for at least 50min at a speed of 50-150 ml/min, and collecting liquid in a stachyose peak-off time period.
According to some embodiments of the invention, the volume ratio of acetonitrile to water in the eluent is 75-80: 20-25. Stachyose can be better eluted at the elution ratio, and higher yield (more than 90%) is obtained.
According to some embodiments of the invention, the high pressure is 20 to 40 bar.
According to some embodiments of the invention, the concentrating and drying operation is: and (3) carrying out vacuum concentration at the vacuum degree of 0.08-0.1 MPa and the temperature of 50-70 ℃, and freeze-drying the concentrated solution to obtain the stachyose.
A method of making an embodiment according to the second aspect of the invention comprises the steps of:
mixing the above materials by equivalent incremental mixing method, and mixing.
The preparation method according to the embodiment of the invention has at least the following beneficial effects: the preparation method of the scheme of the invention is simple to operate, and the equal incremental mixing method is adopted, so that the mixing effect is better.
According to the application of the embodiment of the third aspect of the invention, the solid beverage is used for preparing the solid beverage for assisting in treating intestinal diseases.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
In order to explain the technical content, the objects and the effects of the present invention in detail, the following description will be given with reference to the embodiments. The test methods used in the examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are commercially available reagents and materials unless otherwise specified.
The embodiment of the invention is as follows: a solid beverage for auxiliary treatment of intestinal diseases is prepared from the following raw materials: camel milk powder, goat milk powder, stachyose, oat powder, plantain seed shell powder, phyllostachys pubescens leaf powder, laminaria powder and composite probiotics, wherein the weight parts are shown in the following table 1:
TABLE 1
Wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis, and the mass ratio of the lactobacillus plantarum to the streptococcus thermophilus is 3: 3:4:2:4, viable count 8 x 109CFU/g or so.
And (3) designing a clinical test:
the test population: the test product is suitable for patients with intestinal diseases, the age of the test subject is 25-45 years, the test subject does not have other diseases, the test subject does not take medicines related to the tested functions in a short period, and the test subject is not allergic to the test product.
Grouping tests: according to the intestinal condition and age, 400 subjects were randomly divided into 8 groups of 50 persons each, of which example 4 group, control group 3 group, and blank control group 1 group (with an equal amount of placebo).
The eating method comprises the following steps: the test dose of 8 groups is the same, and the test dose is 2 times per day, 1.5g each time, and the test dose is continuously taken for 30 days.
The results of the clinical trials are detailed in table 2.
TABLE 2
As can be seen from table 2, compared with the blank control group, the test group taking the functional probiotic solid beverage provided by the embodiment of the invention has significant effects of maintaining intestinal health and improving immunity. Compared with the data of the comparative examples, the data of the comparative examples are that the improvement effect of the comparative examples on the intestinal diseases is not obvious, the comparative examples have better effects, the effect can be quickly achieved, the IgA content can be obviously increased, and the IFN-gamma content can be reduced, wherein the effect of the comparative example 3 is the best. The dosage of the components of the invention is shown to be within the weight part range limited by the invention, so as to achieve the effects of maintaining the intestinal health and improving the immunity.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all equivalent modifications made by the present invention in the specification or directly or indirectly applied to the related technical field are included in the scope of the present invention.
Claims (10)
1. A solid beverage for auxiliary treatment of intestinal diseases is characterized in that: the preparation raw materials of the solid beverage comprise: camel milk powder, goat milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys pubescens leaf powder, thallus laminariae powder and composite probiotics;
wherein the composite probiotics comprise lactobacillus plantarum, streptococcus thermophilus, bifidobacterium bifidum, clostridium and lactobacillus lactis.
2. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the preparation raw materials also comprise flavoring agents, and the flavoring agents comprise lemon powder, strawberry powder, orange powder and green plum powder; preferably, the mass ratio of the lemon powder, the strawberry powder, the fragrant orange powder and the green plum powder is (2-3): 1-5): 2-4): 1-3.
3. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the weight ratio of camel milk powder, sheep milk powder, stachyose, oat powder, Plantago ovata shell powder, phyllostachys edulis powder, thallus laminariae powder and composite probiotics is (40-50): 30-35): 2-5): 2-8): 1-5): 1-8): 5-10.
4. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the mass ratio of the lactobacillus plantarum to the streptococcus thermophilus to the bifidobacterium bifidum to the clostridium and the lactobacillus lactis is (2-4) to (2-5) to (2-4) to (1-4) to (3-5).
5. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the number of viable bacteria in the composite probiotics is not less than 109CFU/g。
6. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 1, characterized in that: the preparation method of the stachyose comprises the following steps:
adding cordyceps sinensis and ginseng into water with the temperature of 50-80 ℃, ultrasonically leaching for 1-2 hours, and squeezing to obtain a crude extract;
adding yeast into the crude extract for fermentation to obtain fermentation liquor;
adding quicklime into the fermentation liquor until the fermentation liquor is saturated, heating to 50-55 ℃, and introducing carbon dioxide to generate calcium carbonate precipitate;
filtering, collecting filtrate, purifying, concentrating, and drying to obtain stachyose.
7. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 6, characterized in that: and during ultrasonic leaching, the ultrasonic power is 200-300W.
8. The solid beverage for the adjuvant treatment of intestinal diseases according to claim 6, characterized in that: the purification operation comprises the following steps: performing high-pressure preparative liquid chromatography on the filtrate by using an aminopropyl bonded silica gel column, taking acetonitrile-water as an eluent, performing constant-current elution for at least 50min at a speed of 50-150 ml/min, and collecting liquid in a stachyose peak-off time period; preferably, the volume ratio of acetonitrile to water in the eluent is 75-80: 20-25.
9. The method for preparing a solid beverage for the adjuvant treatment of intestinal diseases according to any one of claims 1 to 8, wherein: the method comprises the following steps:
mixing the above materials by equivalent incremental mixing method, and mixing.
10. Use of the solid beverage according to any one of claims 1 to 8 for the preparation of a solid beverage for the adjuvant treatment of intestinal disorders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010465735.7A CN111700116A (en) | 2020-05-28 | 2020-05-28 | Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010465735.7A CN111700116A (en) | 2020-05-28 | 2020-05-28 | Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111700116A true CN111700116A (en) | 2020-09-25 |
Family
ID=72536953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010465735.7A Pending CN111700116A (en) | 2020-05-28 | 2020-05-28 | Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111700116A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140072649A1 (en) * | 2012-09-11 | 2014-03-13 | Al-Urdonia Lemudaddat Al-Ajsam Co. | Immunized Camel Milk-Based Composition for the Treatment or Prevention of Gastrointestinal Infections |
| CN109198356A (en) * | 2018-11-23 | 2019-01-15 | 温友来 | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal |
| CN109329419A (en) * | 2018-08-28 | 2019-02-15 | 吉林标普生物科技有限公司 | A kind of functional probiotics solid beverage and preparation method thereof for being able to maintain that intestinal health and improving immunity |
| CN110759956A (en) * | 2019-10-25 | 2020-02-07 | 安徽民祯生物工程有限公司 | Preparation method of high-purity stachyose |
-
2020
- 2020-05-28 CN CN202010465735.7A patent/CN111700116A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140072649A1 (en) * | 2012-09-11 | 2014-03-13 | Al-Urdonia Lemudaddat Al-Ajsam Co. | Immunized Camel Milk-Based Composition for the Treatment or Prevention of Gastrointestinal Infections |
| CN109329419A (en) * | 2018-08-28 | 2019-02-15 | 吉林标普生物科技有限公司 | A kind of functional probiotics solid beverage and preparation method thereof for being able to maintain that intestinal health and improving immunity |
| CN109198356A (en) * | 2018-11-23 | 2019-01-15 | 温友来 | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal |
| CN110759956A (en) * | 2019-10-25 | 2020-02-07 | 安徽民祯生物工程有限公司 | Preparation method of high-purity stachyose |
Non-Patent Citations (7)
| Title |
|---|
| 中国优生科学协会: "《乖宝宝每周营养方案》", 31 July 2007, 吉林科学技术出版社 * |
| 任建存等: "《牛羊生产》", 31 August 2012, 河南科学技术出版社 * |
| 刘继芳等: "《畜牧兽医最新实用技术选编2016》", 31 December 2016, 中国农业大学出版社 * |
| 卢卫红等: "《食品功能原理及评价》", 31 October 2014, 哈尔滨工业大学出版社 * |
| 谢梦洲等: "《中医药膳学》", 30 November 2016, 中国中医药出版社 * |
| 郑建仙等: "《功能性食品学》", 30 November 2019, 中国轻工业出版社 * |
| 韦剑锋等: "《科技论文写作与文献检索》", 31 March 2017, 天津科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108685094B (en) | Traditional Chinese medicine enzyme and preparation method thereof | |
| JP2005506063A (en) | Probiotic Lactobacillus salivarius strains | |
| TWI759126B (en) | Anti-inflammation and treatment of inflammatory disorders with liquid culture of lactic acid bacteria strains | |
| CN109123295A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN106413724B (en) | Lactobacillus rhamnosus RHT-3201 conjugated with polysaccharide polymer binder and uses thereof | |
| WO2007030975A1 (en) | New usage of tremella fuciformis heteropolysaccharide or extract thereof | |
| CN105942128A (en) | Herbal yeast probiotic solid beverage and making method and application thereof | |
| CN106819106B (en) | Preparation method of inactivated fermented milk beverage with immunoregulation function | |
| CN111345453A (en) | Composite probiotic powder for intestinal tract | |
| JP5348716B2 (en) | Immunostimulator and method for producing the same | |
| CN114642260B (en) | Litchi ferment, and preparation method and application thereof | |
| JP2010202557A (en) | Nk activity enhancer | |
| CN111575204A (en) | Lactobacillus paracasei capable of relieving or treating allergic diseases and application thereof | |
| CN111329055A (en) | Preparation method of trifoliate acanthopanax enzyme | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN111700116A (en) | Solid beverage for adjuvant therapy of intestinal diseases and preparation method and application thereof | |
| CN104256656A (en) | Full-nutrition formulated food for fatty acid metabolic disorder | |
| RU2322995C1 (en) | Biopreparation of veterinary indication and method for preventing gastro-intestinal diseases in neonatal calves due to its application | |
| CN102742654B (en) | Beautification probiotic ewe milk tablet and preparation method thereof | |
| CN110892914A (en) | New application of lactobacillus paracasei K56 in improvement of asthma and related allergic symptoms | |
| CN109730154A (en) | A kind of probiotics donkey milk piece and preparation method thereof | |
| CN115989871A (en) | Composition for promoting growth and development as well as preparation method and application thereof | |
| CN113040392A (en) | Composite preparation containing ovalbumin peptide | |
| CN113144167A (en) | Fermented small-molecule peptide mixed solution with uric acid reducing effect and preparation method and application thereof | |
| KR102502978B1 (en) | Composition for Anti-inflammation or Enhancing Immunity Comprising Surface Layer Protein of Lactic Acid Bacteria from Kefir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200925 |
|
| RJ01 | Rejection of invention patent application after publication |